Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $12.67 Average PT from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been assigned an average recommendation of "Buy" from the ten brokerages that are currently covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $12.67.

A number of research analysts have recently commented on CMPX shares. Guggenheim reduced their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Wedbush restated an "outperform" rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. D. Boral Capital restated a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Monday, April 28th. Finally, Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st.

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded up $0.22 during mid-day trading on Friday, reaching $2.92. The company's stock had a trading volume of 906,937 shares, compared to its average volume of 980,509. Compass Therapeutics has a 12-month low of $0.87 and a 12-month high of $4.08. The company has a market capitalization of $403.79 million, a P/E ratio of -7.12 and a beta of 1.48. The firm's fifty day moving average price is $2.33 and its two-hundred day moving average price is $2.35.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.12). On average, research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. MPM Bioimpact LLC lifted its holdings in shares of Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after acquiring an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC bought a new stake in Compass Therapeutics in the fourth quarter worth $11,293,000. Tang Capital Management LLC lifted its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after purchasing an additional 150,336 shares during the last quarter. Finally, Blue Owl Capital Holdings LP lifted its stake in Compass Therapeutics by 2.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after purchasing an additional 75,000 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.